Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12720913 | 0.88 | HRH1 (0.47) | KCNH2HRH1TAAR1CYP3A4TSHR | |
| SCHEMBL522831 | 0.85 | KCNH2 (0.56) | KCNH2HRH1CYP2A6NOS1NOS2 | |
| SCHEMBL14835167 | 0.80 | KCNH2 (0.43) | KCNH2CYP3A4TSHRMBOAT4NOS1 | |
| SCHEMBL11903968 | 0.80 | KCNH2 (0.62) | KCNH2CYP3A4TSHRMBOAT4NOS2 | |
| SCHEMBL14835224 | 0.80 | KCNH2 (0.43) | KCNH2CYP3A4TSHRMBOAT4ALDH1A1 | |
| SCHEMBL31190859 | 0.79 | — | — | |
| SCHEMBL904618 | 0.79 | — | — | |
| SCHEMBL14834386 | 0.78 | KCNH2 (0.46) | KCNH2HRH1CYP3A4TSHRMBOAT4 | |
| SCHEMBL4718869 | 0.78 | NOS1 (0.46) | KCNH2HRH1NOS1NOS2 | |
| SCHEMBL28474866 | 0.77 | KCNH2 (0.40) | KCNH2CYP3A4TSHRMBOAT4NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078406-B2 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | Life Technologies Corporation | 2004-12-09 | — | — | US | disclosed |
| US-6815445-B2 | FOR USE AS FLUORESCENCE DYES AND PROBES | Life Technologies Corporation | 2004-11-09 | — | — | US | disclosed |
| EP-1442027-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2003031419-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | KCNH2 3759/4885HRH1 1821/4885TAAR1 2085/4885 |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | KCNH2 3759/4885HRH1 1821/4885TAAR1 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.